Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer
Status:
Recruiting
Trial end date:
2025-02-01
Target enrollment:
Participant gender:
Summary
This early phase I trial aims to determine how cobimetinib or olaparib works in patients with
pancreatic cancer. Validation of cobimetinib and olaparib molecular targets will be explored
by comparing pre-treatment biopsies with post-treatment specimens. This knowledge will help
design future biomarker driven trials to determine whether giving cobimetinib or olaparib
will work better than standard treatments in patients with pancreatic cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborators:
National Cancer Institute (NCI) Oregon Health and Science University